Cognitive Neuroscience Market Size & Share, by Component (Software, Hardware, Services); Technology; Application; End user; Disease Type; Source - Global Supply & Demand Analysis, Growth Forecasts, Statistical Report 2026-2035

Cognitive Neuroscience Market - Regional Analysis

North America Market Insights

North America in the cognitive neuroscience market is projected to hold the highest share of 42.5% by the end of 2035. The market’s growth in the region is highly fueled by the presence of robust government-based funding, as well as an increase in advanced neurotechnology implementation. In this regard, the February 2022 Cambridge Organization report indicated that the region has been readily dominating brain-computer interfaces (BCI), with a total revenue of 40% over the past 6 years. Additionally, in terms of the civilian population, 69% of respondents in the U.S. have been integrating BCI technologies for enhancing their neurological conditions, thereby suitable for the market’s growth in the overall region.

The cognitive neuroscience market in the U.S. is significantly growing, owing to the aspects of federal funding, the presence of Medicaid and Medicare reimbursement services, private sectors, and administrative support. For instance, as of November 2024, the American Psychological Association Inc. deliberately joined the brain health community with the objective to urge administrative bodies to initiate a fund of USD 5 million for the FDA’s Neurology Drug Program. This successfully ensured the appropriation process to provide generous funding to conduct research regarding neurological illness, which affects 1 in 5 adults in the country.

The cognitive neuroscience market in Canada is also growing due to initiatives undertaken by the government, along with innovation in neurotechnology, healthcare reforms, clinical and pharmaceutical trials, and cross-border partnerships. According to the May 2024 Government of Canada report, undertook the decision to generously invest USD 800 million as part of the strategic science fund (SSF) to boost research and innovation for the latest advancements in the market. In addition, the Budget 2024 made the provision of USD 825 million to support master’s, doctoral and post-doctoral students, thereby denoting a vision for future scientists in the neuroscience field.

Medicaid and Medicare Payment Policy Modifiers in North America

Source: Federal Register Government, November 2023

APAC Market Insights

Asia Pacific in the market is expected to be the fastest-growing region, with a share of 22.1% during the forecast period. The market’s upliftment in the region is effectively propelled by government-aided research, AI integration, and a rise in neurological diseases. As per the September 2022 NLM report, 64.4 million people in South-East Asia suffer from neurological diseases, accounting for 95% of the uncertainty interval. This is followed by 85.0 million in West Pacific regions, constituting a similar uncertainty interval. Besides, the 2025 NLM article has noted that the neurological disease burden in the overall region is usually high among the male population between 65 and 74 years, thus enhancing the market demand.

The cognitive neuroscience market in China is gaining increased traction, owing to an increase in the patient pool readily suffering from cognitive disorders, along with organizational contributions to launch platforms or products to aid these diseases. For instance, in November 2024, UCB announced the closing of its neurology portfolio in the country, including Zhuhai, Xyzal, Zyrtec, Neupro, Vimpat, Keppra manufacturing facilities. All these facilities were handed over to Mubadala Investment Company and CBC Group for an enterprise valuation of USD 680 million, which ensured that patients in the country will have access to standard treatment options.

The cognitive neuroscience market in India is gaining increased exposure, owing to a surge in healthcare expenditure, particularly for neurological diagnostics. Besides, as per the 2021 NITI Aayog report, there has been healthcare investments in the country, wherein the industry accounts for a valuation of USD 372 billion as of 2022. In addition, the NSDC has estimated that the industry also deployed 7.5 million people within the same year by providing 2.7 million opportunities, which accounts for 500,000 jobs per year. Therefore, this positively caters to development in the cognitive neuroscience market in the country to provide suitable solutions for cognitive and neurological diseases.

Neurological Diseases Comparison Between South-East Asia and West Pacific

Source: NLM, September 2022

Europe Market Insights

Europe is expected to hold a considerable cognitive neuroscience market share of 28.3% during the projected timeline. The market’s development in the region is highly driven by regional funding initiatives, AI adoption, and an increase in neurodegenerative disorders. As per an article published by the UK Research and Innovation in October 2022, neurodegenerative disorders in the overall region are associated with the age factor, and at present, 16% of the population is more than 65 years of age, which is projected to increase to 25% by the end of 2030. Additionally, it is predicted that 1 million people from the UK will be diagnosed with dementia by the end of 2025 due to which the present expense of the economy is £26 billion per year.

The cognitive neuroscience market in Germany has been steadily growing since there has been an increase in demand, as well as the willingness of organizations to conduct thorough research. For instance, in February 2023, the country’s Federal Institute for Drugs and Medical Devices (BfArM) successfully cleared NeuroSense’s Clinical Trial Application (CTA) to register patients in PARADIGM. This is considered the Phase 2b clinical study of its PrimeC, which is a notable combination drug candidate, suitable for aiding amyotrophic lateral sclerosis (ALS), thus denoting a positive outlook for the overall market in the country.

The cognitive neuroscience market in the UK is also growing due to an upsurge in budget allocation and administrative regulations. In this regard, there has been a robust public support for creating an alignment between the country’s approach with international standards on the grounds of medical device regulation. According to the October 2024 Neurotechnology report, there has been the provision of 80% of support for the alignment with Europe MDR, as well as 56% support for the International Medical Devices Regulatory Forum (IMDRF) alignment. Therefore, with such developments and support from different administrative organizations, the market is bolstering in the country.